I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| hepatocyte | 3 studies | 46% ± 13% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| hepatocyte | 3 studies | 46% ± 13% |
Insufficient scRNA-seq data for expression of SLC22A9 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 943.38 | 226 / 226 | 93% | 51.79 | 377 / 406 |
| brain | 56% | 30.28 | 1485 / 2642 | 2% | 0.03 | 13 / 705 |
| pancreas | 51% | 7.29 | 166 / 328 | 7% | 0.36 | 12 / 178 |
| kidney | 25% | 2.25 | 22 / 89 | 5% | 0.20 | 43 / 901 |
| esophagus | 19% | 1.82 | 271 / 1445 | 4% | 0.29 | 7 / 183 |
| stomach | 16% | 1.32 | 57 / 359 | 4% | 0.09 | 11 / 286 |
| lung | 17% | 1.87 | 97 / 578 | 1% | 0.05 | 13 / 1155 |
| uterus | 9% | 1.01 | 16 / 170 | 1% | 0.03 | 3 / 459 |
| skin | 8% | 0.87 | 151 / 1809 | 0% | 0.00 | 1 / 472 |
| intestine | 6% | 0.43 | 56 / 966 | 1% | 0.08 | 7 / 527 |
| prostate | 4% | 0.26 | 10 / 245 | 1% | 0.01 | 4 / 502 |
| peripheral blood | 3% | 0.28 | 28 / 929 | 0% | 0 | 0 / 0 |
| breast | 3% | 0.23 | 13 / 459 | 0% | 0.00 | 2 / 1118 |
| ovary | 3% | 0.23 | 5 / 180 | 0% | 0.00 | 1 / 430 |
| adipose | 3% | 0.22 | 34 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 2% | 1.34 | 5 / 241 | 0% | 0 | 0 / 0 |
| blood vessel | 2% | 0.12 | 24 / 1335 | 0% | 0 | 0 / 0 |
| heart | 1% | 0.08 | 9 / 861 | 0% | 0 | 0 / 0 |
| thymus | 1% | 0.05 | 6 / 653 | 0% | 0 | 0 / 605 |
| adrenal gland | 1% | 0.05 | 2 / 258 | 0% | 0 | 0 / 230 |
| muscle | 0% | 0.03 | 4 / 803 | 0% | 0 | 0 / 0 |
| bladder | 0% | 0 | 0 / 21 | 0% | 0.00 | 1 / 504 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0009914 | Biological process | hormone transport |
| GO_0015913 | Biological process | short-chain fatty acid transmembrane transport |
| GO_0015711 | Biological process | organic anion transport |
| GO_0043252 | Biological process | sodium-independent organic anion transport |
| GO_0016323 | Cellular component | basolateral plasma membrane |
| GO_0008514 | Molecular function | organic anion transmembrane transporter activity |
| GO_0015347 | Molecular function | sodium-independent organic anion transmembrane transporter activity |
| GO_0015636 | Molecular function | short-chain fatty acid transmembrane transporter activity |
| Gene name | SLC22A9 |
| Protein name | Organic anion transporter 7 (OAT7) (Organic anion/short-chain fatty acid exchanger) (Solute carrier family 22 member 9) |
| Synonyms | hOAT4 UST3 OAT7 |
| Description | FUNCTION: Sodium-independent organic anion transporter, exhibits high specificity for sulfated conjugates of xenobiotics and steroid hormones such as estrone 3-sulfate (E1S) and dehydroepiandrosterone sulfate (DHEAS) . Can transport the statin pravastatin and may contribute to its disposition into the hepatocytes when the function of OATPs is compromised . It is specifically activated by 3 to 5 carbons-containing short-chain fatty acids/SCFAs, including propionate (propanoate), butyrate (butanoate) and valerate (pentanoate) . May operate the exchange of sulfated organic components against short-chain fatty acids/SCFAs, in particular butanoate, at the sinusoidal membrane of hepatocytes . . |
| Accessions | Q8IVM8 ENST00000279178.4 [Q8IVM8-1] ENST00000536333.5 [Q8IVM8-2] |
